Errata to the FDA Briefing Document
Meeting of the Anesthesia and Analgesia Advisory Committee
January 10, 2025

This errata contains corrections to FDA's briefing information for the January 2025 Meeting of the Anesthetic and Analgesic Drugs Products Advisory Committee. At this meeting, the Committee will discuss biologics license application (BLA) 761393, condoliase injection, submitted by Seikagaku (SKK) for the proposed indication of "the treatment of radicular leg pain associated with confirmed nerve root impingement caused by lumbar disc herniation in adults"

Page 6, Paragraph 3:

> FDA Briefing Document reads:
> "*If approved, this would be the first drug or biologic product approved for the treatment of RLP, and it would be the only product currently on the market for intradiscal injection for any indication.*"
>
> Clarification: As discussed in Section 2.2 of the Briefing Document, chymopapain (NDA/BLA 18663) was approved in 1983 for "treatment of patients with documented herniated lumbar intervertebral discs whose symptoms and signs, particularly sciatica, have not responded to an adequate period or periods of conservative therapy." Chymopapain was withdrawn from the US market in 2001.

Page 11: Pertinent Drug Development and Regulatory History

> The fourth paragraph, first sentence should read, "Condoliase digests chondroitin sulfate, which is a prominent component"

Page 15: Study 1133 Key Selection Criteria

> The sixth bullet point under "Inclusion Criteria" should read, "Radicular pain must be in one leg only and present for ≥6 weeks but ≤12 months"

Page 21: Footnote of Figure 2

> Should read, "Source: Integrated Summary of Efficacy, page 78"

Page 21: Study 1131 Synopsis and Results

> The first paragraph, fifth sentence should read, "Study 1131 failed to demonstrate efficacy on the primary endpoint"

Page 22: Study 1031 Synopsis and Results

> The first paragraph, third sentence should read, "Study 1031 treated 163 patients, with"

Page 40-41: Prespecified Imaging Findings by Visit
Corrected table is below.

Table 13. Prespecified Imaging Findings by Visit (Population: Primary Safety Pool: Phase 2/3 Controlled Studies)

Visit Category	SI-6603 1.25 U (N = 578) n (%)	SI-6603 >1.25 U (N = 98) n (%)	Pooled Placebo (N = 128) n (%)	Sham Control (N = 268) n (%)	Pooled Placebo/Sham Pooled (N = 396) n (%)
Baseline					
Vertebral posterior angle flexion >=5 degrees	12/574 (2.1)	9/98 (9.2)	6/128 (4.7)	0/268	6/396 (1.5)
Vertebral body translation of >=3 mm	5/574 (0.9)	1/98 (1.0)	0/128	0/268	0/396
Modic Type 1	137/577 (23.7)	15/98 (15.3)	12/128 (9.4)	61/268 (22.8)	73/396 (18.4)
Modic Type 2	98/577 (17.0)	3/98 (3.1)	24/128 (18.8)	51/268 (19.0)	75/396 (18.9)
Modic Type 3	4/577 (0.7)	0/98	0/128	3/268 (1.1)	3/396 (0.8)
Week 6					
Decrease from baseline in disc height >=30%	5/395 (1.3)	8/97 (8.2)	0/124	0/89	0/213
Vertebral posterior angle flexion >=5 degrees	8/395 (2.0)	9/97 (9.3)	4/124 (3.2)	0/89	4/213 (1.9)
Vertebral body translation of >=3 mm	1/392 (0.3)	1/97 (1.0)	1/124 (0.8)	0/89	1/213 (0.5)
Modic Type 1	152/397 (38.3)	37/97 (38.1)	14/124 (11.3)	25/89 (28.1)	39/213 (18.3)
Modic Type 2	62/397 (15.6)	3/97 (3.1)	22/124 (17.7)	24/89 (27.0)	46/213 (21.6)
Modic Type 3	4/397 (1.0)	0/97	0/124	3/89 (3.4)	3/213 (1.4)
Modic Change from 'No' to 'Yes' [1]					
Modic Type 1	62/305 (20.3)	22/82 (26.8)	2/112 (1.8)	2/65 (3.1)	4/177 (2.3)
Modic Type 2	1/326 (0.3)	0/94	0/101	0/65	0/166
Modic Type 3	0/393	0/97	0/124	0/86	0/210
Week 13					
Decrease from baseline in disc height >=30%	20/512 (3.9)	10/91 (11.0)	0/112	0/238	0/350
Vertebral posterior angle flexion >=5 degrees	7/514 (1.4)	10/91 (11.0)	2/112 (1.8)	0/237	2/349 (0.6)
Vertebral body translation of >=3 mm	1/512 (0.2)	1/91 (1.1)	3/112 (2.7)	2/235 (0.9)	5/347 (1.4)
Modic Type 1	231/521 (44.3)	39/91 (42.9)	14/112 (12.5)	62/238 (26.1)	76/350 (21.7)
Modic Type 2	81/521 (15.5)	3/91 (3.3)	20/112 (17.9)	44/238 (18.5)	64/350 (18.3)
Modic Type 3	3/521 (0.6)	0/91	0/112	2/238 (0.8)	2/350 (0.6)
Modic Change from 'No' to 'Yes' [1]					
Modic Type 1	104/391 (26.6)	25/77 (32.5)	4/102 (3.9)	9/184 (4.9)	13/286 (4.5)
Modic Type 2	2/432 (0.5)	0/88	0/92	0/194	0/286
Modic Type 3	0/518	0/91	0/112	0/236	0/348

(continued on next page)

Visit Category	Pooled SI-6603 1.25 U (N = 578) n (%)	Pooled SI-6603 >1.25 U (N = 98) n (%)	Pooled Placebo (N = 128) n (%)	Pooled Sham Control (N = 268) n (%)	Pooled Placebo/Sham Pooled (N = 396) n (%)
Week 26					
Decrease from baseline in disc height >=30%	21/329 (6.4)	9/82 (11.0)	0/101	0/75	0/176
Vertebral posterior angle flexion >=5 degrees	8/331 (2.4)	8/82 (9.8)	4/101 (4.0)	0/74	4/175 (2.3)
Vertebral body translation of >=3 mm	3/329 (0.9)	0/82	2/101 (2.0)	0/74	2/175 (1.1)
Modic Type 1	154/336 (45.8)	38/82 (46.3)	20/101 (19.8)	24/77 (31.2)	44/178 (24.7)
Modic Type 2	57/336 (17.0)	3/82 (3.7)	19/101 (18.8)	20/77 (26.0)	39/178 (21.9)
Modic Type 3	3/336 (0.9)	0/82	0/101	1/77 (1.3)	1/178 (0.6)
Modic Change from 'No' to 'Yes' [1]					
Modic Type 1	75/253 (29.6)	24/68 (35.3)	10/91 (11.0)	4/56 (7.1)	14/147 (9.5)
Modic Type 2	6/270 (2.2)	0/79	0/82	0/57	0/139
Modic Type 3	0/333	0/82	0/101	0/76	0/177
Week 52					
Decrease from baseline in disc height >=30%	27/438 (6.2)	14/76 (18.4)	0/89	1/202 (0.5)	1/291 (0.3)
Vertebral posterior angle flexion >=5 degrees	11/437 (2.5)	5/76 (6.6)	6/89 (6.7)	1/199 (0.5)	7/288 (2.4)
Vertebral body translation of >=3 mm	4/434 (0.9)	0/76	0/89	1/199 (0.5)	1/288 (0.3)
Modic Type 1	201/439 (45.8)	37/76 (48.7)	24/89 (27.0)	63/200 (31.5)	87/289 (30.1)
Modic Type 2	79/439 (18.0)	3/76 (3.9)	18/89 (20.2)	39/200 (19.5)	57/289 (19.7)
Modic Type 3	3/439 (0.7)	0/76	0/89	1/200 (0.5)	1/289 (0.3)
Modic Change from 'No' to 'Yes' [1]					
Modic Type 1	106/334 (31.7)	25/64 (39.1)	15/80 (18.8)	19/152 (12.5)	34/232 (14.7)
Modic Type 2	15/358 (4.2)	0/73	0/71	2/161 (1.2)	2/232 (0.9)
Modic Type 3	0/436	0/76	0/89	0/199	0/288
Week 104					
Decrease from baseline in disc height >=30%	14/192 (7.3)	NA	NA	0/71	0/71
Vertebral posterior angle flexion >=5 degrees	1/192 (0.5)	NA	NA	0/71	0/71
Vertebral body translation of >=3 mm	1/190 (0.5)	NA	NA	0/71	0/71
Modic Type 1	79/194 (40.7)	NA	NA	23/68 (33.8)	23/68 (33.8)
Modic Type 2	59/194 (30.4)	NA	NA	24/68 (35.3)	24/68 (35.3)
Modic Type 3	2/194 (1.0)	NA	NA	1/68 (1.5)	1/68 (1.5)
Modic Change from 'No' to 'Yes' [1]					
Modic Type 1	41/146 (28.1)	NA	NA	6/50 (12.0)	6/50 (12.0)
Modic Type 2	18/147 (12.2)	NA	NA	5/48 (10.4)	5/48 (10.4)
Modic Type 3	0/192	NA	NA	0/67	0/67
Last Post-Baseline Visit					
Decrease from baseline in disc height >=30%	35/554 (6.3)	14/98 (14.3)	0/127	1/249 (0.4)	1/376 (0.3)
Vertebral posterior angle flexion >=5 degrees	10/555 (1.8)	6/98 (6.1)	6/127 (4.7)	1/248 (0.4)	7/375 (1.9)
Vertebral body translation of >=3 mm	4/553 (0.7)	1/98 (1.0)	1/127 (0.8)	1/246 (0.4)	2/373 (0.5)
Modic Type 1	249/555 (44.9)	45/98 (45.9)	28/127 (22.0)	75/249 (30.1)	103/376 (27.4)
Modic Type 2	107/555 (19.3)	3/98 (3.1)	23/127 (18.1)	52/249 (20.9)	75/376 (19.9)
Modic Type 3	5/555 (0.9)	0/98	0/127	3/249 (1.2)	3/376 (0.8)
Modic Change from 'No' to 'Yes' [1]					
Modic Type 1	128/422 (30.3)	30/83 (36.1)	16/115 (13.9)	22/192 (11.5)	38/307 (12.4)
Modic Type 2	25/461 (5.4)	0/95	0/103	6/202 (3.0)	6/305 (2.0)
Modic Type 3	1/551 (0.2)	0/98	0/127	0/246	0/373

NA = not applicable; U = unit

[1] Percent of subjects with modic change from No to Yes from baseline are out of subjects that do not have 'Yes' at baseline for that Modic type and have non-missing data at that visit.

Note: All other percentages are based on the number of subjects with image results at each visit.

Note: Baseline is the last non-missing measurement observed prior to the study injection.

Note: Study 6603/1133 did not evaluate imaging findings at Weeks 6 and 26. Week 104 was evaluated for Study 6603/1131 only.

Source: Integrated Summary of Safety, Table 35 (modified for clarity)

Page 41: Summary of Modic Changes

The sixth bullet point under “Inspection of Table 13 shows that:” should read, “patients with progression from no Modic finding or Modic Type 1 to Modic Type 2”